首页 > 期刊杂志 > 正文

Role of the Biomarker p16 in Downgrading -IN 2 Diagnoses and Predicting Higher-grade Lesions.

生物标记p16在-IN2诊断降级和预测更高级别病变中的作用

Maniar KP,Sanchez B,Paintal A,Gursel DB,Nayar R

Abstract

In 2012, the College of American Pathologists and American Society for Colposcopy and Cervical Pathology published the "LAST" recommendations for histopathology reporting of human papilloma virus-related squamous lesions of the lower anogenital tract, including the use of a 2-tier nomenclature (low-grade squamous intraepithelial lesion/high-grade squamous intraepithelial lesion [LSIL/HSIL]) and expanded use of the biomarker p16 to classify equivocal lesions as either precancer (HSIL) or low-grade lesions (LSIL)/non-human papilloma virus changes. We aimed to determine (1) the frequency with which the poorly reproducible diagnosis of intermediate-grade (-IN 2) lesion in the lower anogenital tract would be downgraded on the basis of p16 results, and (2) whether p16 status was predictive of subsequent higher-grade lesions. A total of 200 specimens diagnosed as an intermediate-grade (-IN 2) lesion of the cervix (168), vagina (2), vulva (2), and anus (28) were reviewed and immunostained for p16. Slides were independently reviewed by 2 pathologists, with discrepant p16 interpretations adjudicated by a third pathologist. Of the 200 cases, 32% were negative for p16. Among the 166 patients with subsequent pathology (including 131 excisions), 26.2% of p16-positive cases versus 4.4% of p16-negative cases were associated with a subsequent diagnosis of HSIL (-IN 3) or worse (P=0.002). Reproducibility of the biopsy diagnosis was fair, with no significant difference with the addition of p16 or using 2 versus 3 tiers. In 11.5% of cases, there was discordance in p16 interpretation (κ 0.735, good agreement). The results indicate that using the Lower Anogenital Squamous Terminology recommendations would result in approximately one third of equivocal (-IN 2) diagnoses being downgraded to LSIL over 1 year in a busy academic practice. The significant association of p16 expression with a higher risk for HSIL on a subsequent specimen suggests that use of p16 to adjudicate equivocal (-IN 2) diagnoses in lower anogenital tract specimens as either LSIL or HSIL would likely predict lesion grade more accurately and avoid unnecessary excisional procedures.

摘要

2012年,美国病理学家协会和美国阴道镜及宫颈病理学协会发表了“LAST( Lower Anogenital Squamous Terminology)”推荐意见,对女性生殖道下段及肛门人类乳头状瘤病毒相关性鳞状细胞病变的病理报告提出了建议,包括使用两级命名法(LSIL/HSIL)、使用生物标记p16将模棱两可的病变归类为癌前病变(HSIL)或LSIL/非人类乳头状瘤病毒改变。本文目的是要确定:(1)根据p16染色结果而将女性生殖道下段及肛门诊断重复性差的-IN2病变降级的发生频率;(2)p16染色状态是否能预测更高级别病变。我们复习了200例诊断为-IN2的标本,其中宫颈168例、阴道2例、外阴2例、肛门28例,并进行了p16免疫组化检测。由2名病理医生独立复查切片,p16判读结果有差异的病例由另外1名病理医生裁定。200例IN2标本中,p16免疫染色阴性的有32%。随后有病理学检测的166名患者(包括131例行切除治疗的患者)中,p16阳性病例占26.2%,p16阴性病例占4.4%,p16阳性与随后病理诊断HSIL或更严重病变相关(P=0.002)。活检诊断的重复性好,辅助p16检测或使用2级分类法与3级分类法相比无明显差异。11.5%的病例p16判读不一致(κ= 0.735, 一致性好)。我们的研究结果表明,使用“LAST”推荐意见会导致日常繁忙的医疗活动中1年时间内大约有1/3模棱两可的-IN2诊断降级为LSIL。p16表达与发生HSIL高风险之间显著相关,提示我们:使用p16染色用于裁定女性生殖道下段及肛门标本模棱两可的-IN2诊断为LSIL或HSIL,可能会更准确预测病变级别,避免不必要的切除治疗。

full text

我要评论

0条评论